



Mr. Binoy Yohannan  
Associate Vice President – Surveillance  
M/s. National Stock Exchange of India Ltd  
Exchange Plaza, Bandra Kurla Complex  
**Mumbai 400 051**  
**Script Code: NATCOPHARM**

1st July, 2024

Sub: Clarification /Confirmation on news item appearing in Media / Publication

Dear Sirs,

To clarify, we have not spoken to the reporter covering the stated article on the Hindu Business Line captioned **“Natco Pharma mulling acquisition in RoW market to strengthen base business”** dated June 28, 2024. Our analysis of this news article points out that all aspects of this news article came from already publicly disclosed materials available with stock exchange filings made by NATCO Pharma Limited from time to time. The clarification sought by you is mentioned below:

- a) Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.

*We wish to state that the headline **“Natco Pharma mulling acquisition in RoW market to strengthen base business”** is a public knowledge and has been conveyed to the shareholders and stock exchanges at large through Investor Concalls submissions on November 21, 2023 and June 4, 2024. The same has been stated in our Investor Presentation submitted to stock exchanges dated May 29, 2024.*

*NATCO Pharma has also committed to invest US\$ 2 million or ₹ 15.01 crores in Cellogen Therapeutics Private Limited (“Cellogen”) across three tranches for a fully diluted stake of 5.38% and definitive agreements have been signed to that effect. Out of which, first tranche of ₹ 7.51 crores has already been invested in Cellogen Therapeutics. Cellogen is a research company involved in cell and gene therapies. Its advanced programme is related to development of CAR-T therapy. The same has been communicated to Stock Exchange vide press release dated January 17, 2024.*

- b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.

*The Company has not withheld any material information or events which, in our opinion, would impact the movement in the price of our securities. In case of any information or event that requires disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we will make the necessary disclosures in accordance with regulatory requirements.*

- c) The material impact of this article on the Company.

*There is no material impact of this article on the Company.*

Further, the news portion about the buyback and crop health business and the position of NATCO on this matter has already been communicated to shareholders and stock exchanges through Investor Concall submission on June 4, 2024

Thanking you  
Yours faithfully  
For NATCO Pharma Limited

Venkat Ramesh Ch  
Company Secretary &  
Compliance Officer